[1]周玉凤.放射性核素标记小分子多肽治疗肿瘤的研究进展[J].国际放射医学核医学杂志,2005,29(3):105-108.
　ZHOU Yu-feng.The recent development of receptor targeting therapy for tumors with radiopeptides[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):105-108.
点击复制

放射性核素标记小分子多肽治疗肿瘤的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
29
期数:
2005年第3期
页码:
105-108
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The recent development of receptor targeting therapy for tumors with radiopeptides
作者:
周玉凤
226361 南通, 江苏省南通市肿瘤医院核医学科
Author(s):
ZHOU Yu-feng
Department of Nuclear Medicine, Nantong Tumor Hospital, Nantong 226361, China
关键词:
放射性标记; 多肽; 肿瘤; 生长抑素
Keywords:
radiolabeled; polypeptide; tumor; somatostatin
分类号:
R817.5
摘要:
近年来,应用放射性核素标记多肽进行受体靶向治疗在肿瘤治疗领域已变得非常重要。临床应用最多的是生长抑素类似物。现已成功开发出放射性核素标记的α-黑色素细胞刺激激素、神经紧张素、血管活性肠肽、铃蟾肽、P物质、神经肽Y、缩胆囊素类似物等,并已进行体内、外研究。综述了应用90Y和177Lu标记的生长抑素类似物进行受体介导放射性核素靶向治疗的情况,以及放射性核素标记的缩胆囊素和神经肽Y用于内照射治疗的前期临床资料。
Abstract:
Receptor targeting therapy with radiolabeled peptides has become very important in oncology in the past few years. The most frequently used peptides in the clinic are analogs of somatostatin. Radiolabeled analogs of alpha-melanocyte-stimulating hormone, neurotensin, vasoactive intestinal peptide, bombesin, substance P, neuropeptide Y, gastrin and cholecystokinin are also being developed and evaluated in vitro and in vivo. This review focuses on the state of the art of the pre-clinical and clinical studies on 90Y and 177Lu radiolabeled somatostatin analogs for receptor-mediated radionuclide targeting therapy. Early clinical data of radiolabeled cholecystokinin and neuropeptide Y for internal radiopeptide therapy are also reviewed.

参考文献/References:

1 Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases[J]. Apple Radiat Isot, 2002, 57(5):749-763.
2 Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies[J]. Semin Nucl Med, 2002, 32(2):123-132.
3 Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with[In-DTPA] octreotide:the Rotterdam experience[J]. Semin Nucl Med, 2002, 32(2):110-122.
4 Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular for in vivo multireceptor tomour targeting[J]. Eur J Ncul Med Mol Imaging, 2002, 29(7):855-862.
5 Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of the somatostatin receptor subtypes2,3 and 5 forLabelling with various radiometals[J]. Eur J Nucl Med Mol Imaging, 2003, 30(10):1338-1347.
6 Kwekkeboom DJ, Kooij PP, Bakker WH, et al. Comparison of 111InDOTA-Thy3-octreotide and 111In-DTPA-octreotide in the same patients:biodistribution, kinetics organ and tumor uptak[J]. J Nucl Med, 1999, 40(5):762-767.
7 Chinol M, Bodei L, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-dphe-Thy-octreotide:the experience of the European Institute of Oncology Group[J]. Semin Nucl Med, 2002, 32(2):141-147.
8 Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4GBq 90Y-DOTATOC[J]. J Nucl Med, 2002, 43(5):610-616.
9 Waldherr C, Schumacher T, Maecke HR, et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90-yttrium-DOTATOC in neuroendocrine tumors?[J].Eur J Nucl Med, 2002, 29(Suppl):S100.
10 De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors:preclinical and clinical findings[J].Semin Nucl Med, 2002, 32(2):133-140.
11 Jonard P, Jamar F, Walrand S, et al. Tumor dosimetry based on PET86Y-DOTA-Tyr3-octreotide(SMT487)and CT-scan predicts tumor response to 90Y-SMT487(OctreoTher)[J]. J Nucl Med, 2000, 41(Suppl):111P.
12 Schumacher T, Hofer S, Eichhorn k, et al. Local injection of the 90Ylabelled peptidc vector DOTATOC to control gliomas of WHO grades Ⅱ and Ⅲ:an extended pilot study[J]. Eur J Nucl Med Mol Imaging,2002, 29(4):486-493.
13 Virgolini I, Britton K, Buscombe J, et al. In-and Y-DOTA-lanreotide:results and implications of the MAURITIUS trial[J]. Semin Nucl Med,2002, 32(2):148-155.
14 Kwekkeboom DJ, Bakker WH, Kooij PPM, et al.[177Lu-DOTAO,Thy3] octreotate:comparison with[111In-DOTA0] octreotide in patiens[J]. EurJ Nucl Med, 2001, 28(9):1319-1325.
15 Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patient with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue[177Lu-DOTA (0), Thy3] octreotate[J].EurJ Nucl Med Mol Imaging, 2003, 30(3):417-422.
16 Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate:relation to neoplastic transformation[J]. Cancer Res,1999, 59(5):1152-1159.
17 Gugger M, Reubi JC. Gastrin-releasing peptide receptors in nonneoplastic and neoplastic human breast[J]. Am J Pathol, 1999, 155(6):2067-2076.
18 De Jong M, Breeman WA, Bernard BF, et al. Tumor Response After[(90)Y-DOTA(0), Thy(3)] octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size[J]. Eur J Nucl Med, 2001,42(12):1841-1846.
19 De Jong M, Beraard BF, Breeman WAP, et al. Combination of 90Yand 177Lu-labelled somatostatin analogs is superior for radionuclide therapy compared to 90Y-or 177Lu-labelled analogs only[J]. J Nucl Med,2002, 43(Suppl):123P-124P.

相似文献/References:

[1]罗全勇.多肽受体靶向放射治疗:现状与进展[J].国际放射医学核医学杂志,2005,29(2):74.
　LUO Quan-yong.Peptide receptor radionuclide therapy: current status and future directions[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):74.
[2]向艳,夏劲松.生长抑素类似物及其标记核素[J].国际放射医学核医学杂志,2002,26(1):21.
　XIANG Yan,XIA Jin-song.Recent development of radio-labeled somatostatin analogues as receptor image agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(3):21.
[3]杨永青.标记免疫分析在心血管疾病中的临床价值及其进展[J].国际放射医学核医学杂志,2000,24(5):193.
　YANG Yong-qing.The clinical applications of labelling immunoassay in the cardiovascular disease and its progress[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(3):193.
[4]王晓青,谢毓元.以多肽导向的靶向造影剂的研究[J].国际放射医学核医学杂志,1996,20(2):49.

备注/Memo

备注/Memo:
收稿日期:2004-08-19。
更新日期/Last Update: 1900-01-01